Klaus Dachselt

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

Wolfram Pönisch, Paris S. Mitrou, K Merkle et al. · Journal of Cancer Research and Clinical Oncology · 2006 · 192 citations · Full text

Medicine, Hematology, Oncology +13

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

Michael Herold, Antina Schulze, Dietger Niederwieser et al. · Journal of Cancer Research and Clinical Oncology · 2005 · 103 citations · Full text

Medicine, Oncology, Pharmacology +14

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

Michael Herold, R. Pasold, Stefanie Srock et al. · Blood · 2004 · 72 citations

Medicine, Oncology, Pharmacotherapy +13

Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients^†

Carsten Hirt, Frank Schüler, Thomas Kiefer et al. · British Journal of Haematology · 2008 · 43 citations · Full text

Medicine, Hematology, Oncology +13